GlassScriptPhysician profile
Hung D Quan
NPI 1639263023
$4,854.90
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $165 · 2021: $167 · 2022: $1,338 · 2023: $1,428 · 2024: $926.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350 · Travel and Lodging: $4.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,350.33 |
| Travel and Lodging | $4.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $863.87 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $747.26 | 2019-2024 | Evenity, Otezla, Repatha |
| Lilly USA, LLC | $522.56 | 2019-2024 | Mounjaro, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.93 | 2023 | Xifaxan, Trulance |
| Optinose US, INC. | $241.65 | 2019-2020 | |
| Novo Nordisk INC | $177.04 | 2021-2024 | Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $160.74 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.78 | 2022-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $150.56 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $146.11 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $145.37 | 2022-2023 | Nuzyra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2023 | |
| Horizon Therapeutics Plc | $124.78 | 2023 | Tepezza |
| Phathom Pharmaceuticals, INC. | $124.51 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $124.36 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $122.64 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.63 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.28 | 2019 | |
| Urovant Sciences INC | $80.90 | 2022 | |
| Dynavax Technologies Corporation | $53.96 | 2019-2021 | |
| Glaxosmithkline, LLC. | $51.29 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.11 | 2024 | |
| Redhill Biopharma INC. | $31.58 | 2021-2023 | Talicia |
| Eisai INC. | $22.18 | 2022 | |
| Amarin Pharma, INC. | $21.98 | 2020 | |
| Zimmer Biomet Holdings, INC. | $21.98 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Pfizer INC. | $19.79 | 2023 | |
| Insmed, INC. | $19.28 | 2023 | Arikayce |
| Merck Sharp & Dohme LLC | $19.10 | 2022 | |
| Oyster Point Pharma, INC. | $18.67 | 2023 | Tyrvaya |
| Janssen Pharmaceuticals, INC | $18.28 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.88 | 2019 | |
| Cequr Corporation | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Quan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.